Purity 99% Pharmaceutical Trelagliptin Succinate

Payment Type: L/C,T/T
Incoterm: FOB,CIF
Min. Order: 25 Kilogram
Delivery Time: 5 Days

Basic Info

Model No.: cy1029877-94-8

Pharmaceutical Intermediate: CAS NO 540737-29-9

Additional Info

Packaging: 25kg

Productivity: 10000

Brand: cy

Transportation: Ocean,Land,Air

Place of Origin: China

Supply Ability: 10

Certificate: GB/T 16483.GB/T 17519

HS Code: 2907299090

Port: QINGDAO,SHANGHAI

Product Description


CAS:
330792-69-3
MF:
C17H12N2O2
MW:
276.28938
EINECS:
Synonyms:
Propanedinitrile, 2-[Methoxy(4-phenoxyphenyl)Methylene]-;2-(Methoxy(4-phenoxyphenyl)Methylene)Malononitrile;1,1-Dicyano-2-methoxy-2-(4-phenoxyphenyl)ethene;2-[Methoxy(4-phenoxyphenyl)methylene]propanedinitrile;2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile;Intermediate of Ibrutinib, Note separate 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile

The COA of this product :

ITEMS

SPECIFICATION

TESTRESULTS

Appearance

Off-white or white powder

Conforms

Identification

HPLC,NMR;LC-MS

Conforms

Related substances

Individual impurity≤0.5%

0.09%

Total impurities≤1.0%

0.20%

Loss on drying

≤0.5%

0.3%

Residue on ignition

≤0.1%

0.04%

Heavy metals

≤10ppm

Conforms

Assay

≥98.0 %

99.1%

 

Product name

Trelagliptin succinate

CAS NO.

1029877-94-8

Synonyms

Trelagliptin succinate

Category

Pharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.

Purity

99% Trelagliptin succinate

Appearance

Trelagliptin succinate powder

Shelf life

2 years

Usage

Trelagliptin succinate is an antidiabetic drug. Trelagliptin succinate is used to improve glycemic control in people with type 2 diabetes

Storage

Trelagliptin succinate should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.


Description:
 
SYR-472 is a novel once-weekly oral DPP-4 inhibitor for type 2 diabetes, which could be a treatment option when clinicians seek to improve medication adherence by reducing the number of required administrations.
 
In study, The incidence of treatment-emergent adverse events in each SYR-472 group was similar to that in the placebo group. The most common adverse event was nasopharyngitis in all groups. No episodes of hypoglycaemia defined by investigator occurred with any treatment during the study. Once-weekly SYR-472 treatment produced clinically and statistically significant improvements in glycaemic control in patients with type 2 diabetes. It was well tolerated and might be a new treatment option for patients with this disease.

 



Contact Information

CONTACT US

Shandong Chenyi Environmental Protection Technology Co.,Ltd

Contact Person: Jerry

Phone:86-0531-18560179988

Fax:

Address: No.215 Beiyuan Main street,tianqiao District,Jinan,Shandong

Full name Contact Phone Content
点击刷新验证码